NAUT Nautilus Biotechnology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NAUT

Price (delayed)

$0.9539

Market cap

$121.39M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.45

Enterprise value

$136.04M

?
Relative Growth: Rel. Growth: 7
Relative Strength: Rel. Strength: 6
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 31

With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology ...

Highlights
Nautilus Biotechnology's net income has increased by 14% YoY
NAUT's EPS is up by 13% year-on-year and by 2.2% since the previous quarter
The quick ratio has contracted by 46% YoY and by 15% from the previous quarter
The equity has decreased by 28% YoY and by 9% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.nautilus.bio
Peers: NTLA CRSP EDIT FATE

Key stats

What are the main financial stats of NAUT

NAUT stock price

How has the Nautilus Biotechnology stock price performed over time
Intraday
-4.55%
1 week
-1.87%
1 month
-0.06%
1 year
31.52%
YTD
-51.08%
QTD
-48.99%

Financial performance

How have Nautilus Biotechnology's revenue and profit performed over time
Revenue
$190,000
Gross profit
$175,000
Operating income
-$62.78M
Net income
-$56.52M
Gross margin
92.1%
Net margin
-29,747.9%
Nautilus Biotechnology's operating income has increased by 16% YoY and by 2.1% from the previous quarter
Nautilus Biotechnology's net income has increased by 14% YoY

Price vs fundamentals

How does NAUT's price correlate with its fundamentals

Growth

What is Nautilus Biotechnology's growth rate over time

Valuation

What is Nautilus Biotechnology stock price valuation
P/E
N/A
P/B
0.92
P/S
638.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
715.99
NAUT's EPS is up by 13% year-on-year and by 2.2% since the previous quarter
The stock's price to book (P/B) is 49% less than its last 4 quarters average of 1.9 and 31% less than its 5-year quarterly average of 1.4
The equity has decreased by 28% YoY and by 9% from the previous quarter

Efficiency

How efficient is Nautilus Biotechnology business performance
The return on equity has declined by 16% year-on-year and by 7% since the previous quarter
NAUT's return on assets is down by 10% year-on-year and by 5% since the previous quarter
The ROIC is down by 7% year-on-year and by 3.1% since the previous quarter

Dividends

What is NAUT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NAUT.

Financial health

How did Nautilus Biotechnology financials performed over time
The quick ratio has contracted by 46% YoY and by 15% from the previous quarter
The current ratio fell by 45% YoY and by 14% QoQ
Nautilus Biotechnology's debt is 79% lower than its equity
Nautilus Biotechnology's debt to equity has increased by 31% YoY and by 5% from the previous quarter
The equity has decreased by 28% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.